Related Experiment Video
Updated: May 15, 2026
09:15
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
Published on: July 18, 2019
Sodium oxybate intolerance associated with familial serum acylcarnitine elevation
1Woodinville Psychiatric Associates, Woodinville, WA 98072, USA. jonbernermd@yahoo.com
Summary
Two families showed sodium oxybate intolerance, presenting as dystonia or eating disorders, linked to elevated acylcarnitines. This suggests mitochondrial disorders may impact medication tolerability for sleep disturbances.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Sodium oxybate is used to treat disturbed sleep.
- Identifying predictors of poor response to sodium oxybate is crucial for patient care.
- Genetic and metabolic factors may influence drug tolerability.
Observation:
- Two families presented with joint phenotypes: sodium oxybate intolerance and elevated serum acylcarnitines.
- Oxybate intolerance manifested as cervical dystonia or sleep-related eating disorder.
- These families exhibited familial inheritance patterns and multiorgan system involvement.
Findings:
- Elevated serum acylcarnitines suggest a potential fatty acid oxidation defect.
- The observed phenotypes and inheritance patterns point towards a possible mitochondrial disorder.
- This suggests a link between mitochondrial dysfunction and sodium oxybate intolerance.
Implications:
- Mitochondrial disorders may represent a secondary cause of sodium oxybate intolerance.
- Variations in human mitochondrial metabolism could affect the tolerability of sodium oxybate.
- Understanding these links can inform personalized treatment strategies for sleep disorders.
Related Concept Videos
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...